- Home
- ZBAI vs MIRA Comparison
ZBAI vs MIRA Comparison
Compare ZBAI & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- MIRA
- Stock Information
- Founded
- ZBAI 2015
- MIRA 2020
- Country
- ZBAI United States
- MIRA United States
- Employees
- ZBAI N/A
- MIRA N/A
- Industry
- ZBAI Professional Services
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- MIRA Health Care
- Exchange
- ZBAI Nasdaq
- MIRA Nasdaq
- Market Cap
- ZBAI 16.8M
- MIRA 18.4M
- IPO Year
- ZBAI N/A
- MIRA 2023
- Fundamental
- Price
- ZBAI $1.08
- MIRA $1.10
- Analyst Decision
- ZBAI
- MIRA Strong Buy
- Analyst Count
- ZBAI 0
- MIRA 2
- Target Price
- ZBAI N/A
- MIRA $14.00
- AVG Volume (30 Days)
- ZBAI 1.6M
- MIRA 226.5K
- Earning Date
- ZBAI 03-04-2025
- MIRA 03-31-2025
- Dividend Yield
- ZBAI N/A
- MIRA N/A
- EPS Growth
- ZBAI N/A
- MIRA N/A
- EPS
- ZBAI N/A
- MIRA N/A
- Revenue
- ZBAI $495,000.00
- MIRA N/A
- Revenue This Year
- ZBAI N/A
- MIRA N/A
- Revenue Next Year
- ZBAI N/A
- MIRA N/A
- P/E Ratio
- ZBAI N/A
- MIRA N/A
- Revenue Growth
- ZBAI N/A
- MIRA N/A
- 52 Week Low
- ZBAI $0.58
- MIRA $0.51
- 52 Week High
- ZBAI $2.50
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- ZBAI N/A
- MIRA 43.36
- Support Level
- ZBAI N/A
- MIRA $1.09
- Resistance Level
- ZBAI N/A
- MIRA $1.18
- Average True Range (ATR)
- ZBAI 0.00
- MIRA 0.06
- MACD
- ZBAI 0.00
- MIRA -0.00
- Stochastic Oscillator
- ZBAI 0.00
- MIRA 7.69
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.